Skip to main content

SNN · Smith & Nephew PLC

Track SNN — free
$30.17 +0.34 (+1.14%)
Market Cap
$12.47B
Shares
418.11M
Volume · Nov 19 1.16M Avg daily vol (3M) 1.54M

Price & Indicators

 

Key stats

Close
$29.83
Open
$30.02
Day range
$29.79–30.11
52-week closing range
$26.42–36.90
Average volume, 30 days
1.4M
Short interest
4.4M · 1.1% of shares · 3.7 days
Short volume, last session
53%
Last earnings
Aug 4, 2026
Price history
Jan 2020 to Nov 2026

Up next

Apr 7, 2027 Est · unconfirmed · in 20 wks

Latest documents

2026
Nov 18
Current report 6-K
Executives buy ADS via dividend reinvestment plan after interim dividend

Smith & Nephew reports Chief Executive Officer Deepak Nath and three other managers bought American Depositary Shares at $31.2097 each through the Employee Stock Purchase Plan and Dividend Re-Investment Plan following the 2026 interim dividend paid on 6 November 2026.

4 source passages
Director and PDMRs are participants of the Company's Employee Stock Purchase Plan, which purchased American Depository Shares through the Company's Dividend Re-Investment Plan following the 2026 interim dividend payment on 6 November 2026. Deepak Nath (Chief Executive Officer) Director | 31.2097 | 36.34448 | N/A Single Transaction Open the document at this passage
Nov 12
Current report 6-K
Executives purchase shares through dividend reinvestment plan

Smith & Nephew plc executives purchased ordinary shares through the company’s Dividend Re-Investment Plan on 2026 – 11 – 06 at 11.676693 per share, following the 2026 interim dividend payment on 6 November 2026.

4 source passages
Smith & Nephew plc Purchase of ordinary shares through the Company’s Dividend Re-Investment Plan following the 2026 interim dividend payment on 6 November 2026. Date of Transaction | 2026 – 11 – 06 Deepak Nath (Chief Executive Officer) | Director | 11.676693 | 4354.91595 | N/A Single Transaction Open the document at this passage
Nov 4
Current report 6-K
Guidance cut as US Orthopaedics growth slows

Smith+Nephew reported Q3 revenue of $1,551 million, up 3.4%, as Sports Medicine momentum offset weak US Orthopaedics. Full-year underlying revenue growth guidance fell to around 3%, trading profit growth to around 4%, and free cash flow to around $750 million.

6 source passages
Smith+Nephew (LSE:SN, NYSE:SNN) trading update for the quarter ended 26 September 2026. Q3 revenue of $1,551 million (Q3 2025: $1,501 million), representing 3.4% revenue growth on both an underlying and reported basis (Q3: 63 trading days, in line with Q3 2025): We have revised our full-year guidance to reflect the slower growth in US Orthopaedics, which we expect to continue through the fourth quarter. Full year underlying revenue growth of around 3% (previously “around 4%”). trading profit growth is now expected to be around 4% (previously “around 8%”), with around $1.25 billion of trading profit (previously “around $1.3 billion”) including marginal dilution from the Integrity acquisition Free cash flow is now expected to be around $750 million (previously “around $800 million”), with strong trading cash conversion of around 95%, in line with original guidance Open the document at this passage
Nov 4
Current report 6-K
Full-year guidance lowered as Q3 revenue grows 3.4%

Smith+Nephew reported $1,551 million of Q3 revenue, up 3.4%, but cut full-year underlying revenue growth guidance to around 3% from around 4% amid slower US Orthopaedics growth. Free cash flow guidance fell to around $750 million.

4 source passages
Smith+Nephew (LSE:SN, NYSE:SNN) trading update for the quarter ended 26 September 2026. Q3 revenue of $1,551 million (Q3 2025: $1,501 million), representing 3.4% revenue growth on both an underlying and reported basis (Q3: 63 trading days, in line with Q3 2025): Full year underlying revenue growth of around 3% (previously “around 4%”). On a reported basis, the guidance equates to around 4.0% based on exchange rates prevailing on 30 October 2026. Free cash flow is now expected to be around $750 million (previously “around $800 million”), with strong trading cash conversion of around 95%, in line with original guidance Open the document at this passage
Nov 2
Current report 6-K
Issued share capital stands at 837,434,165 voting ordinary shares

Smith & Nephew plc reports that as at 31 October 2026 its total issued share capital is 877,750,024 ordinary shares, including 40,315,859 held in treasury. That leaves 837,434,165 shares with one voting right each, which shareholders should use as the denominator for FCA disclosure thresholds.

2 source passages
the total issued share capital of Smith & Nephew plc (the “Company”) as at 31 October 2026 comprises 877,750,024 ordinary shares of US20¢ each (“ordinary shares”), including 40,315,859 ordinary shares held in treasury. The Company’s issued share capital, with one voting right per share, therefore consists of 837,434,165 ordinary shares. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$6.30B
Trailing 12 months
Net income (TTM)
$635.00M
Trailing 12 months
Revenue growth YoY
+6.1%
Year over year
Operating margin
12.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
2.7%
Trailing 12 months
Shares change YoY
+0.0%
Year over year · more shares
Price change (1Y)
-7.6%
Trailing year
Short interest
1.1%
Latest settlement · 3.7 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Bearish Fundamentals Limited Quant / Vol Moderate
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −3%
below
Price vs 50-day avg +3%
above
RSI (14) 47
neutral
MACD trend Negative
52-week position 33%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −3%
trailing
6-month return +1%
trailing
YTD return −9%
this year
Relative strength +7%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $29 › 200d $31 — 200d above 50d
Institutional flow Distributing
-12% holders QoQ · +15 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.05% of shares out · ▲ +9.0% MoM · 3.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
262 holders — mid 3-yr range
Squeeze score 53
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Moderate
Volatility 27%
annualized · 1-yr
Max drawdown −28%
past year
ATR 2.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Dec 31, 2025
2026
Trading profit $1.3B
Free cash flow $800M
Organic revenue growth Non-GAAP 6%
midterm (2026 through 2028)
Organic revenue compound annual growth rate Non-GAAP 6% – 7%
Trading profit CAGR Non-GAAP 9% – 10%
2026 year-on-year
China profit decline $15M – $20M
Prior guidance period ended · from the Earnings Call filed Dec 31, 2025
Greater China sales · 2025 $160M
China profit impact · 2025 $50M – $60M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−3% Neutral
Price vs 50-day avg
+3% Bullish
RSI (14)
47 Neutral
MACD trend
Negative Bearish
52-week position
33% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $29 › 200d $31 — 200d above 50d
Institutional flow Distributing
-12% holders QoQ · +15 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.05% of shares out · ▲ +9.0% MoM · 3.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
262 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $26 Now $30 · 33% Range high $37
vs 200-day avg -3% vs 50-day avg +3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SNN
Smith & Nephew PLC
this stock
$12.47B -9.1% — — 1.1%
ABT
Abbott Laboratories
$179.90B -17.1% +5.7% 38.8 1.1%
MDT
Medtronic plc
$128.69B +4.7% +8.4% 24.8 1.8%
SYK
Stryker Corp
$119.19B -10.9% +11.2% 33.3 1.7%
BSX
Boston Scientific Corp
$62.31B -54.9% +12.5% 18.2 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
262
% held
8.3%
Net QoQ
-1.8M sh
Top holder
GOLDMAN SACHS GROUP INC
Held Float
View
Held by Funds
Fund positions
44
View
Short & Settlement
Short Interest Rising
Shares short
4.4M
Days to cover
3.7d
Change
+362.4K sh
View
Short Volume
Short vol %
53%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
26.4K
Value
$803.6K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
37.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Alan Armstrong
Amount
$1.0K–$15.0K
Traded
Mar 30, 2026
View
Filings
SEC Filings
Latest
6-K
Filed
Nov 18, 2026
This year
78

Smith & Nephew reports Chief Executive Officer Deepak Nath and three other managers bought American Depositary Shares at $31.2097 each through the Employee Stock Purchase Plan and Dividend Re-Investment Plan following the 2026 interim dividend paid on 6 November 2026.

View
Earnings & Events
Webcasts
Last webcast
Aug 4, 2026
View
Investor Relations
Latest news
Smith+Nephew Third Quarter 2026 T…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
SNN -3.8% -3.4% +1.2% +0.4% -9.1%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +1.7% +2.9% +6.8% +5.7% -14.1%

Capital returns

Latest dividend
$0.312 / share · ex Oct 2, 2026
Cut 35.3%
Paid (TTM)
$0.794 / share · 2 payouts
Dividend yield (TTM, derived)
— · history filling in
Full dividend history

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 845982 CUSIP 83175M205 13F (30d) 261 filings 229 filers Visit website Investor relations